Drug intelligence / Profile preview

HKP102

Development stage: Preclinical
Lead developer: Hankook Korus Pharm
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

HKP102 is a long-acting recombinant erythropoietin (EPO) being developed by Hankook Korus Pharm for the treatment of anemia. The drug is a PEGylated recombinant protein designed to activate the erythropoietin receptor (EPOR), thereby stimulating the production of red blood cells (erythropoiesis). By conjugating the EPO protein with polyethylene glycol (PEG), the molecule achieves a significantly longer half-life compared to conventional erythropoietin, allowing for less frequent dosing. It is currently in the preclinical stage of development.

Other names: PEGylated erythropoietinlong-acting erythropoietin

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on HKP102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKP102.

Explore the full profile